Citations

Clear

4847 citation(s) found for "Tu, Eric".

Unmasking Compound Heterozygosity in GYG1 Myopathy: Diagnostic Insights From RNA ‐Seq and Long‐Read Gen
Panwar, Deepak , Farris, Joseph , Schmidt, Danielle, Blake, Emily J., Tan, Jia W. , Naddaf, Elie, Sonnen, Joshua A. , Vairo, Filippo Pinto e, Lambert, Laura , Wierenga, Klaas J. , Klee, Eric W. , Farris, Joseph D , Sonnen, Joshua , Lambert, Laura J, Muthusamy, Karthik , Panwar, Deepak , Blake, Emily J. , Tan, Jia Wen , Naddaf, Elie , Muthusamy, Karthik

Mayo Clinic

Clinical Genetics | April 23, 2026 | Volume: 110 | Issue: 2 | Pages: 249-253

10.1111/cge.70173 | PMID 42023422 Get It

ABSTRACT Polyglucosan body myopathy type 2 (PGBM2; OMIM #616199) is an autosomal recessive myopathy caused by biallelic variants in GYG1 , which encodes glycogenin‐1. It is characterized by progressive muscle weakness and PAS‐positive, diastase‐resistant polyglucosan inclusions on muscle biopsy. We report a 64‐year‐old woman who developed progressive proximal weakness beginning in her early 50s, with polyglucosan bodies identified on muscle histopathology. Genome sequencing (GS) detected a single heterozygous pathogenic splice‐site variant, NM_004130.4( GYG1 ):c.143+3G>C. Given strong histopathologic evidence of PGBM2, GS data were reanalyzed, revealing an additional rare deep intronic variant, NM_004130.4( GYG1 ):c.7+992T>G, predicted to activate a cryptic exon. RNA sequencing (RNA‐seq) confirmed aberrant splicing from both variants, demonstrating exon 2 skipping associated with c.143+3G>C and cryptic exon inclusion caused by c.7+992T>G. Variant phasing posed a diagnostic challenge due to unavailable parental DNA, and long‐range PCR results were inconclusive. Long‐read GS definitively demonstrated that the two variants were in trans , establishing compound heterozygosity and confirming the molecular diagnosis. These findings enabled reclassification of the deep intronic variant as likely pathogenic. This case highlights the diagnostic limitations of conventional phasing approaches in adult‐onset recessive disorders and demonstrates the clinical utility of integrating genome reanalysis, RNA‐seq, and long‐read GS for resolving complex phasing challenges.
Expert Recommendations for Rapid Response to Positive Newborn Screen for Infantile Krabbe Disease
Thompson-Stone, Robert , White, Amy , Rubin, Jennifer , Rajan, Deepa , Matern, Dietrich , Kurtzberg, Joanne , Orsini, Joseph J. , Shenoy, Shalini , Mallack, Eric J. , Ream, Margie , White, Amy L , Rubin, Jennifer P , Rajan, Deepa Soundara , Ream, Margie A , Kurtzberg, Joanne , Orsini, Joseph J

Mayo Clinic

Neurology Genetics | April 22, 2026 | Volume: 12 | Issue: 3 | Pages: No page available

10.1212/nxg.0000000000200383 | PMID 42040243 Get It

Disseminated Mycobacterium bovis ‐BCG Infection Following Intravesical BCG Administration in Solid Organ Transplant Recipients
Varanasi, Paavana, Wengenack, Nancy L. , Steidley, D. Eric, Kodali, Lavanya , Vikram, Holenarasipur R. , Wengenack, Nancy, Vikram, Holenarasipur R. , Varanasi, Paavana , Steidley, D. Eric

Mayo Clinic

Transplant Infectious Disease | April 21, 2026 | Volume: 28 | Issue: 4 | Pages: No page available

10.1111/tid.70220 | PMID 42012615 Get It

ABSTRACT Background Intravesical Bacillus Calmette–Guerin (BCG) is a live attenuated vaccine for tuberculosis. Intravesical BCG (iBCG) administration is a highly effective immunotherapy for non‐muscle invasive bladder cancer (NMIBC). Although live attenuated vaccines are generally contraindicated in solid organ transplant recipients (SOTR), iBCG has been utilized for NMIBC in SOTR. We describe the clinical manifestations, management, and outcomes of disseminated Mycobacterium bovis ‐BCG infection (Mb‐BCGi) following iBCG therapy in SOTR for NMIBC. Methods All adult patients (> 18 years of age) diagnosed with NMIBC who received iBCG across three tertiary referral and transplant centers between 2000 and 2025 were identified. The study cohort consisted of SOTR who had received iBCG for NMIBC and subsequently developed disseminated Mb‐BCGi. English language literature review was performed to identify additional cases. Results A total of 4207 patients received iBCG during the study period. Thirty (0.71%) were SOTR, of whom two (6.7%) developed disseminated Mb‐BCGi, including bloodstream infection and prostate abscesses. Literature review identified two additional disseminated Mb‐BCGi cases in SOTR with lungs, bloodstream, and native kidney involvement, and one fatality. All cases required extended antimycobacterial therapy. Median times from SOT to Mb‐BCGi and from iBCG to Mb‐BCGi were 104 and 8 months, respectively. Conclusion SOTR appear to be at a higher risk of disseminated Mb‐BCGi following iBCG. Administration of iBCG in SOTR with NMIBC warrants careful risk‐benefit assessment and subsequent close monitoring. image
Imaging the later‐life white matter pathologies of repetitive head impacts: A novel pattern revealed through T2 FLAIR MRI
Groh, Jenna R. , Miner, Annalise E., Alshikho, Mohamad J. , Farris, Chad, Cui, Anna, Pettway, Erika, Labonte, Jacob , Mosaheb, Sydney, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Cantu, Robert C., Dodick, David W., Ashton, Nicholas J., Zetterberg, Henrik, Blennow, Kaj, Peskind, Elaine R. , Nowinski, Christopher, Lenio, Steven, Rabinovici, Gil D., Asken, Breton, Rosen, Howard, Blusztajn, Jan Krzysztof , Budson, Andrew E., Turk, Katherine, Goldstein, Lee, Martin, Brett, Palmisano, Joseph N., Dixon, Diane, Schneider, Greta, Steinberg, Eric G., Su, Yi, Protas, Hillary , Pasternak, Ofer, Bouix, Sylvain, Cummings, Jeffrey L., Reiman, Eric M., Shenton, Martha E., Stern, Robert A., McKee, Ann C., Stein, Thor D., Brickman, Adam M., Mez, Jesse, Alosco, Michael L., Rabinovici, Gil D. , Rabinovici, Gil D , Miner, Annalise E., Farris, Chad W. , Cui, Anna, Pettway, Erika C, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Cantu, Robert C. , Coleman, Michael , Dodick, David W. , Ashton, Nicholas J. , Zetterberg, Henrik , Blennow, Kaj , Ly, Monica T. , Altaras, Caroline , Lenio, Steven , Asken, Breton M. , Cobigo, Yann , Budson, Andrew E. , Turk, Katherine W. , Qiu, Wei Qiao , Palmisano, Joseph , Steinberg, Eric G. , Pasternak, Ofer , Koerte, Inga K , Bouix, Sylvain , Reiman, Eric M. , Shenton, Martha E. , McKee, Ann C. , Stein, Thor D. , Brickman, Adam M. , Mez, Jesse , Alosco, Michael L.

Mayo Clinic

Alzheimer's & Dementia | April 20, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71351 | PMID 42002804 Get It

Abstract INTRODUCTION Repetitive head impacts (RHI) from contact sports may cause a unique pattern of white matter hyperintensities (WMH) on T2‐weighted fluid‐attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI), termed RHI‐associated WMH (RHI‐WMH). These lesions are punctate, circular, and located at the gray–white matter boundary, an area vulnerable to trauma‐related damage. METHODS We investigated the association of RHI with these lesions in two aging cohorts: (1) former American football players versus asymptomatic unexposed men and (2) individuals with RHI from various contact sports versus non‐RHI participants. RHI‐WMH were assessed using visual ratings and a novel automated quantification pipeline. RESULTS Individuals with RHI had greater RHI‐WMH by both detection methods in both cohorts. RHI‐WMH were associated with plasma neurofilament light and p‐tau231, and flortaucipir positron emission tomography (PET) uptake. DISCUSSION RHI‐WMH may represent a new supportive biomarker for the detection of RHI‐related neuropathologies later in life.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies
Ferreira, Daniel, Chmiela, Tomasz , Eriksdotter, Maria, Jack, Clifford R., Marseglia, Anna , Mecocci, Patrizia , Nordberg, Agneta, Westman, Eric, Marseglia, Anna , Mecocci, Patrizia , Chmiela, Tomasz , Ferreira, Daniel , Eriksdotter, Maria , Jack, Clifford R. , Kalpouzos, Grégoria , Nordberg, Agneta , Religa, Dorota , Westman, Eric

Mayo Clinic

Journal of Internal Medicine | April 16, 2026 | Volume: 299 | Issue: 6 | Pages: 694-710

10.1111/joim.70096 | PMID 41988825 Get It

Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms. The most common co‐pathologies in people with AD are alpha‐synucleinopathy, vascular brain injury and transactive response DNA‐binding protein of 43 kDa‐related pathology. Neuroinflammation, iron accumulation, cholinergic dysfunction and cellular senescence are recognized pathobiological processes beyond Aβ‐ and tau‐related pathology. However, the exact mechanisms by which these co‐pathologies and pathobiological processes contribute to the neurodegeneration and clinical symptoms in people with AD remain unclear. The individual combination of these co‐pathologies and pathobiological processes increases phenotypical heterogeneity in people with AD. This highlights the unmet need to advance their current understanding, and the field strives to develop accurate biomarkers for personalized assessment and investigation. Elucidating this biologic‐clinical complexity and heterogeneity is crucial for increasing our current understanding of AD, with implications for diagnosis, prognosis and therapeutics.
National trends in prescription drug expenditures and projections for 2026
Tichy, Eric M. , Rim, Matthew H, Tadrous, Mina, Schumock, Glen T., Cuéllar, Sandra , Johnson, Thomas J., Newell, Mary Kate, Hoffman, James M. , Tadrous, Mina

Mayo Clinic

American Journal of Health-System Pharmacy | April 15, 2026 | Volume: 83 | Issue: 14 | Pages: 728-744

10.1093/ajhp/zxag115 | PMID 42059345 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2026 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2026 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, endocrine drugs, generics, specialty drugs, and vaccines. For nonfederal hospitals, clinics, and overall (all sectors), estimates for growth of pharmaceutical expenditures in 2026 were made based on a combination of quantitative analyses and expert opinion. Results In 2025, overall pharmaceutical expenditures in the US grew 12.7% compared to 2024, for a total of $915.2 billion. Utilization (a 9.3% increase) drove this increase, while growth due to new drugs (0.9%) and price increases (1.2%) had a modest impact. Tirzepatide was the new top drug in 2025, followed by semaglutide and apixiban. Drug expenditures were $42.9 billion (a 9.6% increase) and $190.5 billion (a 19.0% increase) in nonfederal hospitals and in clinics, respectively. In clinics, volume drove drug expense growth, contributing with a 13.6% increase, while price and new drugs each contributed with a 2.7% increase. In nonfederal hospitals, expenditure growth was driven by increases in volume (4.6%), new products (3.7%), and prices (1.5%). Several new drugs that will influence spending are expected to be approved in 2026. Specialty, endocrine, and cancer drugs will continue to drive expenditures. Conclusion For 2026, we expect overall prescription drug spending to rise by 10.0% to 12.0%, whereas in clinics and hospitals we anticipate increases of 14.0%-16.0% and 4.0%-6.0%, respectively, compared to 2025. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending
The Efficacy of Bracing in Nonoperative Care of Medial Femoral Condyle Osteochondritis Dissecans: A Study From the Research in Osteochondritis Dissecans of the Knee (ROCK) Study Group
Group, The ROCK, Nissen, Carl W. , Albright, Jay C. , Anderson, Christian N. , Busch, Michael T., Carey, James L. , Carlson, Cathy , Carsen, Sasha , Crepeau, Allison, Edmonds, Eric W. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John B. , Godin, Jonathan , Ganley, Theodore J. , Grimm, Nathan L. , Heyworth, Benton E. , Po, James Hui Hoi, Kocher, Mininder S., Koehler, Ryan, Latz, Kevin, Loveland, Dustin M., Lyon, Roger M., Meenen, Norbert M., Milewski, Matthew D., Myer, Gregory D., Nelson, Bradley J., Nepple, Jeffrey, Nguyen, Jie C. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Riley, Pat, Saluan, Paul, Shea, Kevin G., Tompkins, Marc , Wall, Eric J. , Willimon, S. Clifton , Wright, Rick W. , Shea, Kevin G. , Edmonds, Eric W , Ellis, Henry B , Fabricant, Peter D , Ganley, Theodore J , Green, Daniel W , Heyworth, Benton E , Krych, Aaron J , Pace, J Lee , Pennock, Andrew T , Perkins, Crystal A , Tompkins, Marc A , Nissen, Carl , Busch, Michael T., Carlson, Cathy, Chambers, Henry G. , Godin, Jonathan, Hui, James Hoi Po, Kocher, Mininder Singh , Koehler, Ryan J. , Krych, Aaron J. , Lyon, Roger, Meenen, N. M., Milewski, Matthew D. , Myer, Gregory D. , Nelson, Bradley J. , Nepple, Jeffrey J. , Weiss, Jennifer M., Wilson, Philip L. , Kostyun, Regina O.

Mayo Clinic

The American Journal of Sports Medicine | April 15, 2026 | Volume: 54 | Issue: 6 | Pages: 1415-1422

10.1177/03635465261429407 | PMID 41981903 Get It

Background: Stable osteochondritis dissecans (OCD) lesions are primarily treated nonoperatively. Nonoperative treatment includes several recommendations, including the use of an unloader brace. However, little is known about the clinical effectiveness of unloader bracing and its influence on OCD healing, return to sports, and patient-reported outcomes (PROs). The purpose of this investigation was to evaluate the impact of unloader bracing on patients with stable medial femoral condyle (MFC) OCD lesions treated nonoperatively. Purpose: To investigate the influence of valgus unloader bracing on the success of treating stable MFC OCD with nonoperative treatment strategies. Study Design: Cohort study; Level of evidence, 2. Methods: The authors used a prospective cohort of patients receiving nonoperative care for stable MFC knee OCD lesions. The primary variable of interest was the efficacy of bracing. The primary outcomes were transition from nonoperative care to surgical intervention, return-to-play (RTP) clearance, and PROs. Bivariate testing was used to determine if there were differences between groups. Chi-square testing was used to determine if there were differences in rates of transition to surgery by group. The timing of the transition by each group was assessed using a Wilcoxon rank-sum test, given the nonparametric nature of the data. Kaplan-Meier survival analysis was used to calculate time at risk, incidence rate, and survival times for each group. Results: A total of 185 knees (bracing group: 123 [66.5%] knees; no-bracing group: 62 [33.5%] knees) were analyzed. Overall, 142 (76.8%) knees were successfully treated nonoperatively. Transition to surgery occurred in 43 (23.2%) knees. There were no differences in transition to surgery by groups, with no differences seen by group. Of the knees that did not transition to surgical care, 65 (71.4%) in the bracing group and 38 (74.5%) in the no-bracing group received RTP clearance ( P = .693). PRO scores were similar between the 2 groups at the time of RTP clearance. Conclusion: The inclusion of an unloader brace in the nonoperative treatment for stable MFC OCD lesions did not decrease the likelihood of patients undergoing surgical intervention or improve their PRO scores at the time of RTP clearance. Registration: NCT02771496 (ClinicalTrials.gov identifier).
Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy
Vodička, Prokop , El-Galaly, Tarec C, Procházka, Vít , Flowers, Christopher R. , Villa, Diego, Dietrich, Caroline E. , Jakobsen, Lasse Hjort , Ghesquieres, Hervé, Clausen, Michael Roost , Kridel, Robert , Hawkes, Eliza A. , Gandhi, Maher K. , Larson, Melissa C, Cahn, Elliot J, Friedberg, Jonathan W. , Martin, Peter, Cohen, Jonathon B. , Habermann, Thomas M, Wang, Y, Mou, Eric , Belada, David, Mocikova, Heidi, Lossos, Izidore S. , Smedby, Karin E, Sehn, Laurie H, Villa, Diego , Jakobsen, Lasse H , Clausen, Michael Roost , Cheah, Chan Yoon , Hawkes, Eliza , Wahlin, Björn , Chihara, Dai , Cohen, Jonathon B , Casulo, Carla , Wang, Yucai , de Nully Brown, Peter , Mou, Eric , Burack, W Richard , Lossos, Izidore S , Kahl, Brad S , Trnĕný, Marek , Cerhan, James R , Maurer, Matthew , Prochazka, Vit , Kridel, Robert , Gandhi, Maher K , El‐Galaly, Tarec Christoffer , Villa, Diego , Ghesquières, Hervé , Cheah, Chan Y. , Larson, Melissa C. , Cahn, Elliot, Chihara, Dai , Habermann, Thomas M. , Casulo, Carla , Brown, Peter de Nully , Belada, David , Janikova, Andrea , Móciková, Heidi , Burack, Richard , Kahl, Brad S. , Smedby, Karin E. , Sehn, Laurie H. , Trněný, Marek , Cerhan, James R. , Maurer, Matthew J. , Vodicka, Prokop

Mayo Clinic

Blood | April 14, 2026 | Volume: 147 | Issue: 26 | Pages: 3248-3252

10.1182/blood.2026033090 | PMID 41980013 Get It

Abstract A short diagnosis-to-treatment interval independently predicts inferior outcomes in follicular lymphoma. Using international discovery and validation cohorts, we demonstrate its prognostic value beyond established prognostic indices, with implications for risk stratification, clinical trial design, and interpretation.
Diabetes as a significant risk factor for postoperative dysphagia following cervical spine surgery
Milne, Catherine, Tippins, Nicholas P., Foreit, Anne M., Alentado, Vincent J. , Bisson, Erica F. , Porche, Ken, Foley, Kevin T, Potts, Eric A. , Milne, Catherine M., Porche, Ken, Foley, Kevin T.

Mayo Clinic

Journal of Neurosurgery: Spine | April 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2025.11.spine25838 | PMID 41962152 Get It

OBJECTIVE This study investigated the relationship between diabetes and the incidence of postoperative dysphagia following cervical spine surgery (CSS). METHODS A prospectively collected multi-institutional quality registry was retrospectively reviewed. Patients who underwent CSS were categorized on the basis of diabetes status, and correlations with preoperative and postoperative Eating Assessment Tool-10 (EAT-10) dysphagia questionnaire scores were assessed. Mixed-effects logistic regressions were performed to examine the impact of preoperative diabetes on postoperative dysphagia. RESULTS Of the 2001 patients who met the inclusion criteria, 400 (20%) had diabetes. Baseline dysphagia rates were not significantly different between groups (18% vs 14%, p = 0.08). Patients with diabetes had a significantly higher incidence of dysphagia at 1 month (66% vs 54%, p = 0.002), 3 months (39% vs 26%, p < 0.001), and 12 months (33% vs 24%, p = 0.004) after surgery compared to patients without diabetes. Including baseline dysphagia as a fixed effect, multivariable analysis indicated that diabetes was a significant predictor of postoperative dysphagia at 1 month (OR 1.46, p = 0.041) and 3 months (OR 1.63, p = 0.001) but not at 12 months (OR 1.21, p = 0.3). In patients with no baseline dysphagia, those with diabetes (329 of 400 [82.3%]) had a significantly higher incidence of new dysphagia than nondiabetics at 1 month (62% vs 50%, p = 0.003), 3 months (34% vs 21%, p < 0.001), and 12 months (27% vs 18%, p = 0.001). The mean change in EAT-10 scores between baseline and 12 months was significantly worse in patients with preoperative diabetes (2.440 ± 5.013 vs 1.688 ± 4.139, p = 0.025). Multivariable analysis indicated that diabetes was a significant predictor of new postoperative dysphagia at 1 month (OR 1.49, p = 0.040) and 3 months (OR 1.81, p < 0.001) but not at 12 months (OR 1.31, p = 0.2). CONCLUSIONS Diabetes is a significant risk factor for experiencing postoperative dysphagia following CSS. Diabetes correlated with higher incidence of dysphagia at all postoperative time points and was a strong independent predictor of postoperative dysphagia at 1 and 3 months.